Adamis Pharmaceuticals Provides Update on the U.S. Launch of SYMJEPI

Adamis Pharmaceuticals (NASDAQ:ADMP) today provided a business update announcing the U.S. launch of FDA-approved SYMJEPI (epinephrine) 0.3mg Injection is planned for early Q1 2019.

As quoted in the press release:

Adamis has continued to work closely with Sandoz Inc., a Novartis division, which has exclusive rights to market and distribute Symjepi in the U.S., to prepare for the U.S. market introduction of this life-saving treatment.  Manufacture of commercial batches has been completed and Adamis will begin shipping to Sandoz distribution centers during December to ensure the appropriate supply for launch.

SYMJEPI (epinephrine) 0.3mg Injection is indicated for the emergency treatment of allergic reactions (Type 1), including anaphylaxis, to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances and other allergens, as well as idiopathic or exercise-induced anaphylaxis. SYMJEPI (epinephrine) 0.3 mg Injection is intended for immediate administration in patients who weigh 66 pounds or more and are determined to be at an increased risk for anaphylaxis.

Click here to read the full press release.